Use of the atmospheric generators for capnophilic bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs

Aurélie Pascual1,2, Leonardo K Basco2, Eric Baret1,2, Rémy Amalvict1,2, Dominique Travers1,2, Christophe Rogier1,2, Bruno Pradines1,2,3*

Abstract

Background: The aim of this study was to evaluate the cultivation system in which the proper atmospheric conditions for growing Plasmodium falciparum parasites were maintained in a sealed bag. The Genbag® system associated with the atmospheric generators for capnophilic bacteria Genbag CO2® was used for in vitro susceptibility test of nine standard anti-malarial drugs and compared to standard incubator conditions.

Methods: The susceptibility of 36 pre-identified parasite strains from a wide panel of countries was assessed for nine standard anti-malarial drugs (chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine, dihydroartemisinin, atovaquone and pyrimethamine) by the standard 42-hour 3H-hypoxanthine uptake inhibition method using the Genbag CO2® system and compared to controlled incubator conditions (5% CO2 and 10% O2).

Results: The counts per minute values in the control wells in incubator atmospheric conditions (5% CO2 and 10% O2) were significantly higher than those of Genbag® conditions (2738 cpm vs 2282 cpm, p < 0.0001). The geometric mean IC50 estimated under the incubator atmospheric conditions was significantly lower for atovaquone (1.2 vs 2.1 nM, p = 0.0011) and higher for the quinolines: chloroquine (127 vs 94 nM, p < 0.0001), quinine (580 vs 439 nM, p < 0.0001), monodesethylamodiaquine (41.4 vs 31.8 nM, p < 0.0001), mefloquine (57.5 vs 49.7 nM, p = 0.0011) and lumefantrine (23.8 vs 21.2 nM, p = 0.0044). There was no significant difference of IC50 between the 2 conditions for dihydroartemisinin, doxycycline and pyrimethamine.

To reduce this difference in term of anti-malarial susceptibility, a specific cut-off was estimated for each drug under Genbag® conditions by regression. The cut-off was estimated at 77 nM for chloroquine (vs 100 nM in 10% O2), 611 nM for quinine (vs 800 nM), 30 nM for mefloquine (vs 30 nM), 61 nM for monodesethylamodiaquine (vs 80 nM) and 1729 nM for pyrimethamine (vs 2000 nM).

Conclusions: The atmospheric generators for capnophilic bacteria Genbag CO2® is an appropriate technology that can be transferred to the field for epidemiological surveys of drug-resistant malaria. The present data suggest the importance of the gas mixture on in vitro microtest results for anti-malarial drugs and the importance of determining the microtest conditions before comparing and analysing the data from different laboratories and concluding on malaria resistance.
Background
Over the past 20 years, many strains of Plasmodium falciparum have become resistant to chloroquine and other anti-malarial drugs [1]. Since 2001, more than 60 countries have officially adopted artemisinin-based combination therapies (ACTs) for the treatment of falciparum malaria [2,3]. However, clinical failures or at least longer parasite clearance times with ACT have been described in Cambodia [4-7]. The emergence and spread of resistance to most of the anti-malarial drugs require intensive research into identifying molecular markers of resistance, as well as implementing in vitro and in vivo surveillance programmes, such as those supported by the Worldwide Antimalarial Resistance Network [8,9].

There are basically three approaches to assess anti-malarial drug susceptibility of P. falciparum: assessment of therapeutic efficacy standardized by the World Health Organization (WHO) [10], in vitro assays and molecular markers of resistance.

In a number of laboratories surveying anti-malarial drug resistance, in vitro tests are performed using the uptake of a radiolabelled nucleic acid precursor \(^{[3]H}\)-hypoxanthine as a marker of parasite growth [11]. Other non-radioactive methods can be used: the WHO schizont maturation test by optical microscopy (Mark III) with pre-dosed plates [12], which was based on the methods of Rieckmann et al. [13] and Wernsdorfer [14], a flow cytometric analysis of propidium iodide incorporation into parasite, which permits a stage-specific evaluation of anti-malarial compounds [15], a fluorescent-based technique that uses SYBR green I which binds to DNA [16,17], and colorimetric or enzyme-linked immunosorbent assays (ELISA) to measure histidine-rich protein II (HRP2) [18,19] or plasmodial lactate dehydrogenase enzyme (pLDH) [20,21].

Many factors induce high variations in P. falciparum growth and 50% inhibitory concentration (IC\(_{50}\)) values and influence the results of the chemosusceptibility tests [22], such as culture medium, initial parasitaemia, haematocrit, incubation time, time point when \(^{[3]H}\)-hypoxanthine is added, use of serum substitutes, storage conditions of sample, delay before cultivation of samples and atmosphere (gas mixtures).

Laboratories using isotopic microtest to monitor drug resistance work at different oxygen tensions: 3% O\(_2\) [15], 5% O\(_2\) \([18,19]\), 10% O\(_2\) \([23,24]\), in candle jars \([20,25]\) (which corresponds to approximately 17-18% O\(_2\)) and >20% O\(_2\) \([21,22]\) (in CO\(_2\) incubators). WHO recommends the use of a candle jar in their in vitro microtests (Mark III). Despite the varying culture conditions, many laboratories have adopted the same threshold for the resistance to anti-malarial compounds under different oxygen tensions. For example, our previous study has shown that the chloroquine IC\(_{50}\) values at 10% O\(_2\) were significantly higher than those at 21% O\(_2\) [26]. Nevertheless, it seems that O\(_2\) concentrations between 1% and 17.5% do not affect the IC\(_{50}\) values of quinoline-containing anti-malarial drugs [27-29]. In contrast, the in vitro anti-malarial activity of some antibiotics was dependent on the O\(_2\) concentration [27].

The aim of this study was to evaluate a cultivation system in which the proper conditions of atmosphere for growing P. falciparum parasites were maintained in an air-tight sealed bag. The Genbag\textsuperscript{®} system was initially designed as atmospheric generators for capnophilic bacteria. Genbag CO2\textsuperscript{®} (BioMérieux; Marcy l’Etoile, France) was used for in vitro susceptibility test of nine standard anti-malarial drugs, and the IC\(_{50}\)s were compared to those obtained with controlled incubator conditions (5% CO\(_2\), 10% O\(_2\) and 85% N\(_2\)).

Methods
Strains of P. falciparum
A total of 36 pre-identified parasite strains (well-characterized laboratory strains or strains obtained from isolates after growth in culture for an extended period of time) from a wide panel of countries were maintained in culture in RPMI 1640 (Invitrogen, Paisley, United Kingdom), supplemented with 10% human serum (Abcys S.A., Paris, France) and buffered with 25 mM HEPES and 25 mM NaHCO\(_3\). Parasites were grown in type A human red blood cells under controlled atmospheric conditions that consisted of 10% O\(_2\), 5% CO\(_2\) and 85% N\(_2\) at 37°C with a relative humidity of 95%. All strains were synchronized twice with sorbitol before use [30]. Clonality was verified using PCR genotyping of polymorphic genetic markers msp1, msp2, and microsatellite loci [31,32]. Chloroquine-susceptible 3D7 clone and chloroquine-resistant W2 clone (MR4 Resource Center) were cultivated in the same conditions and assessed for drug susceptibility in 4 independent experiments.

Drugs
Chloroquine, quinine, dihydroartemisinin, pyrimethamine and doxycycline were purchased from Sigma (Saint Louis, MO). Monodesethylamodiaquine was obtained from the WHO (Geneva, Switzerland). Mefloquine was obtained from Roche (Paris, France). Lumefantrine was provided by Novartis Pharma (Basel, Switzerland), and atovaquone was from GlaxoSmithKline (Evreux, France). Chloroquine and pyrimethamine were dissolved and diluted in water to obtain final concentrations ranging from 5 to 3,200 nM for chloroquine and 5 to 40,000 nM for pyrimethamine. Quinine, monodesethylamodiaquine, mefloquine, dihydroartemisinin, atovaquone and doxycycline were first dissolved in methanol and then diluted in water to obtain final concentrations ranging from 5 to 3,200 nM for quinine,
1.56 to 1000 nM for monodesethylamodiaquine, 3.2 to 400 nM for mefloquine, 0.1 to 100 nM for dihydroartemisinin, 0.3 to 100 nM for atovaquone and 0.1 to 502 μM for doxycycline. Lumefantrine was dissolved and diluted in ethanol to obtain final concentrations ranging from 0.5 to 310 nM.

In vitro assay

For in vitro isotopic microtests, 200 μL/well of a suspension of synchronous parasitized red blood cells (final parasitaemia, 0.5%; final haematocrit, 1.5%) was distributed in 96-well plates predosed with anti-malarial drugs. Parasite growth was assessed by adding 1 μCi of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were incubated for 42 h at 37°C in controlled atmospheric conditions in incubator (5% CO2, 10% O2 and 85% N2) and Genbag® with the atmospheric generators for capnophilic bacteria Genbag CO2® (two plates per sealed bag) (Figure 1). Immediately after incubation, plates were frozen and then thawed to lyse the erythrocytes. The contents of each well were collected on standard filter microplates (Uni-filter GF/B; Perkin-Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin-Elmer). The filter microplates were dried, and 25 μL of scintillation cocktail (Microscint O; Perkin-Elmer) were placed in each well. The radioactivity incorporated into the nucleotides of the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).

The drug concentration that inhibits 50% of parasite growth (IC50) was designated as the concentration at which the tritiated hypoxanthine incorporation reached 50% of the total incorporation by the parasites in the drug-free control wells. The IC50 value was determined by non-linear regression analysis of log-based dose-response curves (Riasmart, Packard, Meriden, USA).

Statistical analysis

Count per minute (cpm) and IC50 were expressed as geometric means and 95% confidence intervals. The differences between the data observed in the incubator and Genbag® were analysed by a paired t-test. The correlation between the responses under two incubation conditions for each anti-malarial drug was estimated by the Pearson correlation coefficient R. The same analyses were performed on IC50 strains/IC50 3D7 or IC50 strains/IC50 W2 ratios calculated for each anti-malarial drug under the two conditions.

Results

A total of 1,098 drug-free control wells were analysed for each experimental condition. A significant difference was observed in the tritiated hypoxanthine uptake between the two conditions with 36 strains of P. falciparum (Table 1). The mean cpm values in the control wells under the controlled incubator conditions (5% CO2 and 10% O2) were significantly higher than those under Genbag® conditions (2738 vs 2282 cpm, p value < 0.0001).

Compared to Genbag® conditions (5% CO2 and 15% O2), the geometric mean IC50 estimated under the incubator atmospheric conditions (5% CO2 and 10% O2) was significantly lower for atovaquone (1.2 vs 2.1 nM, p = 0.0011) and higher for the quinolines: chloroquine (127 vs 94 nM, p < 0.0001), quinine (580 vs 439 nM, p < 0.0001), monodesethylamodiaquine (41.4 vs 31.8 nM, p < 0.0001), mefloquine (57.5 vs 49.7 nM, p = 0.0011) and lumefantrine (23.8 vs 21.2 nM, p = 0.0044) (Table 1). There was no significant difference of IC50 between the two conditions for dihydroartemisinin, doxycycline and pyrimethamine.

The cpm and IC50 values for each anti-malarial drug were highly and significantly correlated between the two conditions (Figure 2, 3 and 4).

Figure 1 The Genbag® system associated with the atmospheric generators for capnophilic bacteria Genbag CO2® with 2 plates in the specific sealed bag (picture P Millileri)
To reduce this difference in terms of anti-malarial susceptibility, a specific cut-off was estimated for each drug under Genbag® conditions by regression. The cut-off was estimated at 77 nM for chloroquine (vs 100 nM in 10% O₂), 611 nM for quinine (vs 800 nM), 30 nM for mefloquine (vs 30 nM), 61 nM for monodesethylamodiaquine (vs 80 nM) and 1729 nM for pyrimethamine (vs 2,000 nM). The cut-off was not re-estimated for drugs for which all the CI₅₀ values were below the cut-off under controlled incubation conditions. For these drugs, median values were estimated: 2.9 nM for atovaquone (vs 2.5 nM in 10% O₂), 26 nM for lumefantrine (vs 30 nM), 3 nM for dihydroartemisinin (vs 3.0 nM) and 15 μM for doxycycline (vs 15 μM).

The geometric mean ratio based on the chloroquine-resistant reference clone 3D7 (strain IC₅₀/3D7 IC₅₀) obtained under the incubator atmospheric conditions (5% CO₂ and 10% O₂) was significantly higher for chloroquine (p < 0.0001), pyrimethamine (p = 0.0026) and was significantly lower for dihydroartemisinin (p < 0.0001) and doxycycline (p = 0.0159) (Table 3).

**Discussion**

The first works that assessed oxygen effects on *P. falciparum* asynchronous cultures had shown that microaerophilic environment allowed an optimal development of parasites [38]. Parasite growth failed under strict anaerobic conditions. *Plasmodium falciparum* possesses a functional mitochondrial respiratory chain with oxygen consumption [39]. It has been shown that there is some protector effect of CO₂ at high oxygen concentration [38] through the medium pH, the stability (between 7.2 and 7.45) of which is required for parasite growth [40]. The standard medium RPMI 1640, buffered with 25 mM HEPES and 25 mM NaHCO₃, was optimized to maintain the pH within the physiological range in an atmosphere containing 5% CO₂. Any modification of the CO₂ concentration alters the pH of the medium, which in turn can influence the IC₅₀ values of pH-dependent drugs, such as quinolines, but not of those that are pH-independent, such as pyrimethamine. Despite similar growth and tritium-labelled hypoxanthine incorporation rates in drug-free control wells, Shenyi He *et al* showed that increasing the CO₂ concentration from 2.7% to 7% (with a constant 5% O₂) resulted in significantly higher...
The chloroquine-resistant K1 strain showed nine-fold greater chloroquine IC50 when the CO2 concentration was increased from 2.7 to 7% [29].

The atmospheric generators for capnophilic bacteria Genbag CO2® evaluated in this study release about 5% CO2 and reduce to 15% O2 in 30 min, according to the manufacturer's specifications (http://www.biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/dynPage?doc=CNL_PRD_CPL_G_PRD_CLN_62). The stated conditions are maintained at least for 48 h. In this context, it seems that the significant differences in drug

Figure 2 Correlation between log IC50 values of chloroquine, quinine or mefloquine, against 36 strains of Plasmodium falciparum under controlled incubator conditions (10% O2) and Genbag® conditions (15% O2).

chloroquine IC50 values [29]. The chloroquine-resistant K1 strain showed nine-fold greater chloroquine IC50 when the CO2 concentration was increased from 2.7 to 7% [29].

The atmospheric generators for capnophilic bacteria Genbag CO2® evaluated in this study release about 5% CO2 and reduce to 15% O2 in 30 min, according to the manufacturer’s specifications (http://www.biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/dynPage?doc=CNL_PRD_CPL_G_PRD_CLN_62). The stated conditions are maintained at least for 48 h. In this context, it seems that the significant differences in drug
IC₅₀ values and growth level (cpm) between the two conditions, the incubator atmospheric conditions (5% CO₂ and 10% O₂) and the Genbag® conditions (5% CO₂ and 15% O₂), are due to the difference in O₂ concentration. The IC₅₀ values of quinoline drugs, such as chloroquine, quinine, monodesethylamodiaquine, mefloquine and lumefantrine were significantly lower at 15% O₂ (Genbag CO₂®) than those at 10% O₂ (the incubator atmospheric conditions). This is in agreement with the
previous results that showed in 136 *P. falciparum* fresh isolates from Comoros that the chloroquine IC$_{50}$ values at 10% O$_2$ were significantly higher than those at 21% O$_2$, with the means of 173.5 nM and 121.5 nM, respectively [26]. Of particular interest among the 63 isolates that were resistant *in vitro* to chloroquine (IC$_{50} >$100 nM) at 5% CO$_2$ and 10% O$_2$, was the observation that 17 were susceptible to chloroquine (IC$_{50} <$100 nM) at 21% O$_2$ [26]. In the present study, only one of 21 strains with chloroquine IC$_{50} >$100 nM at 10% O$_2$ had IC$_{50} <$100 nM.
Table 2 Ratio based on the chloroquine-susceptible reference clone 3D7 (strain IC₅₀/3D7 IC₅₀) of chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and doxycycline against 36 strains of *Plasmodium falciparum* under controlled incubator conditions (10% O₂) and Genbag® conditions (15% O₂)

| Compound                        | O₂ % | IC₅₀ /3D7 IC₅₀ | t-test p-value |
|---------------------------------|------|----------------|---------------|
|                                 | Geometric mean | 95%CI | Min | Max | |
| Chloroquine                     | 10   | 6.88 | 4.15-11.41 | 0.40 | 55.80 | <0.0001 |
|                                 | 15   | 4.80 | 3.09-7.45 | 0.60 | 38.30 | |
| Quinine                         | 10   | 2.44 | 1.90-3.13 | 0.65 | 7.39 | 0.2418 |
|                                 | 15   | 2.63 | 2.04-3.40 | 0.66 | 7.24 | |
| Mefloquine                      | 10   | 0.72 | 0.63-0.82 | 0.39 | 1.64 | <0.0001 |
|                                 | 15   | 0.91 | 0.81-1.03 | 0.49 | 2.089 | |
| Monodesethylamodiaquine         | 10   | 2.59 | 1.80-3.72 | 0.29 | 23.69 | 0.5948 |
|                                 | 15   | 2.52 | 1.73-3.67 | 0.32 | 28.33 | |
| Lumefantrine                    | 10   | 0.90 | 0.74-1.09 | 0.27 | 2.45 | 0.0119 |
|                                 | 15   | 0.81 | 0.67-0.98 | 0.28 | 2.76 | |
| Pyrimethamine                   | 10   | 27.31 | 8.75-85.21 | 1.00 | 1703 | 0.0835 |
|                                 | 15   | 18.01 | 5.51-58.82 | 1.00 | 1494 | |
| Atovaquone                      | 10   | 0.88 | 0.59-1.31 | 0.07 | 5.20 | 0.9187 |
|                                 | 15   | 0.89 | 0.67-1.19 | 0.08 | 4.96 | |
| Dihydroartemisinin              | 10   | 1.53 | 1.27-1.85 | 0.74 | 6.79 | 0.0006 |
|                                 | 15   | 1.31 | 1.04-1.64 | 0.54 | 7.94 | |
| Doxycycline                     | 10   | 1.21 | 1.09-1.35 | 0.85 | 2.90 | 0.0002 |
|                                 | 15   | 1.37 | 1.21-1.55 | 0.80 | 3.11 | |

Table 3 Ratio based on the chloroquine-resistant reference clone W2 (strain IC₅₀/W2 IC₅₀) of chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and doxycycline against 36 strains of *Plasmodium falciparum* under controlled incubator conditions (10% O₂) and Genbag® conditions (15% O₂)

| Compound                        | O₂ % | IC₅₀ /W2 IC₅₀ | t-test p-value |
|---------------------------------|------|----------------|---------------|
|                                 | Geometric mean | 95%CI | Min | Max | |
| Chloroquine                     | 10   | 0.26 | 0.16-0.43 | 0.02 | 2.12 | 0.0014 |
|                                 | 15   | 0.21 | 0.14-0.33 | 0.03 | 1.71 | |
| Quinine                         | 10   | 0.71 | 0.56-0.90 | 0.19 | 2.04 | 0.0006 |
|                                 | 15   | 0.56 | 0.43-0.74 | 0.12 | 1.65 | |
| Mefloquine                      | 10   | 0.97 | 0.66-1.42 | 0.43 | 1.82 | 0.6262 |
|                                 | 15   | 0.82 | 0.72-0.92 | 0.43 | 1.85 | |
| Monodesethylamodiaquine         | 10   | 0.49 | 0.34-0.70 | 0.06 | 4.47 | <0.0001 |
|                                 | 15   | 0.37 | 0.25-0.54 | 0.05 | 4.14 | |
| Lumefantrine                    | 10   | 1.25 | 1.03-1.52 | 0.37 | 3.42 | <0.0001 |
|                                 | 15   | 0.94 | 0.78-1.15 | 0.32 | 3.21 | |
| Pyrimethamine                   | 10   | 0.03 | 0.01-0.10 | 0.001 | 1.96 | 0.0026 |
|                                 | 15   | 0.02 | 0.01-0.07 | 0.0008 | 1.26 | |
| Atovaquone                      | 10   | 0.65 | 0.44-0.97 | 0.05 | 3.85 | 0.8646 |
|                                 | 15   | 0.67 | 0.50-0.89 | 0.06 | 3.71 | |
| Dihydroartemisinin              | 10   | 1.06 | 0.88-1.28 | 0.51 | 4.70 | <0.0001 |
|                                 | 15   | 1.55 | 1.24-1.94 | 0.65 | 9.41 | |
| Doxycycline                     | 10   | 1.16 | 1.05-1.29 | 0.81 | 2.78 | 0.0159 |
|                                 | 15   | 1.25 | 1.10-1.42 | 0.73 | 2.85 | |
at a concentration of 15%. Some studies failed to show oxygen-dependent effects of chloroquine on *P. falciparum* in culture [27-29], but in these experiments less than four strains were tested. Shenyi He *et al* reported that the chloroquine IC50 values determined in a candle jar (2.7% CO2 and 17.5% O2) were similar to those determined in an incubator set at 2.7% CO2 and 5% O2 [27]. Lin *et al* observed similar chloroquine IC50 values with parasites incubated in 5% CO2 and 5% or 15% O2 generated by an AnaeroPack system [29].

In contrast, there was no significant difference of IC50 values between 10% and 15% O2 conditions for doxycycline, dihydroartemisinin and pyrimethamine. Divo *et al* reported that the anti-malarial activity of different cyclines was O2-dependent and higher at high O2 concentrations [27]. Nevertheless, this influence of O2 was not evident at 48 h but was profound at 96 h. In the present study, IC50 values were only determined at 42 h. The class of artemisinins contains an intramolecular peroxide bridge that is situated in the sesquiterpene lactone backbone structure. The anti-malarial potency of artemisinin was enhanced by oxygen and inhibited by oxygen radical scavengers [41,42]. The contrast between 10 and 15% O2 is probably not high enough to observe any difference in dihydroartemisin IC50 values.

Using the threshold values for in vitro resistance established under the controlled incubator conditions (5% CO2 and 10% O2), 0 - 40% of discordant results, depending on the test compounds, was obtained using the Genbag® incubation system. The effect of gas mixture on the results of chemosusceptibility assay should lead different laboratories involved in anti-malarial resistance survey to adapt a resistance threshold for each gas mixture or to use the same conditions to perform chemosusceptibility microtests. The cut-off value was re-estimated for each drug in Genbag® conditions. The cut-off was estimated at 77 nM for chloroquine (vs 100 nM in 10% O2), 611 nM for quinine (vs 800 nM), 30 nM for mefloquine (vs 30 nM), 61 nM for monodesethylamodiaquine (vs 80 nM) and 1729 nM for pyrimethamine (vs 2000 nM).

To reduce the effects of O2 on IC50 values between 10% and 15% O2, the ratios of strain IC50/3D7 IC50 and strain IC50/W2 IC50 were calculated for each condition. Nevertheless, the mean ratios were not similar at 10% and 15% O2 for most anti-malarial drugs, and the results depended on the reference clone.

Conclusions

The atmospheric generators for capnophilic bacteria Genbag CO2® is an appropriate technology that can be transferred to the field for epidemiological surveys of drug-resistant malaria. The present data suggest the importance of the gas mixture on *in vitro* microtest results for anti-malarial drugs and the importance of determining the microtest conditions before comparing and analysing the data from different laboratories and concluding on malaria resistance.

Acknowledgements

This work was supported by the French Ministry of Defense. The views and opinions are those of the authors and do not purport to represent those of the French Ministry of Defense.

Authors’ contributions

LKB and BP conceived and designed the experiments. AP, EB, RA and DT performed the *in vitro* experiments. CR and BP analysed the data. AP, LKB, CR and BP wrote the paper. All authors read and approved the final manuscript.

Conflict of interest

The authors declare that they have no competing interests.

Received: 12 September 2010 Accepted: 14 January 2011
Published: 14 January 2011
mefloquine, quinine, amodiaquine, sulfadoxine/pyrimethamine and artesminin. WHO/CTD/MAL/97.20 Rev 2 Geneva: WHO: 2001.
13. Rieckmann KH, Campbell GH, Sax Li, Mrema JE: Drug sensitivity of Plasmodium falciparum. An in-vitro microtechnique. Lancet 1978, 1:22-23.
14. Wehmowski WH: Field evaluation of drug resistance in malaria. In vitro micro-test. Acta Trop 1980, 37.222-227.
15. Conteras CE, Rivas MA, Dominguez J, Charris J, Palacios M, Bianco NE, Blanca I: Stage-specific activity of potential antimalarial compounds measured in vitro by flow cytometry in comparison to optical microscopy and hypoxanthine uptake. Mem Inst Oswaldo Cruz 2004, 99:179-184.
16. Bacon JR, Latour C, Lucas C, Collina O, Ringwald P, Picot S: Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother 2007, 51:1172-1178.
17. Rason MA, Randraitsoa TA, dranantena H, Ratsimbaosa A, Manerd D: Performance and reliability of the SYBR green I-based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg 2008, 102:346-351.
18. Noedl H, Wehmowski WH, Miller RS, Wongrichanalai C: Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob Agents Chemother 2002, 46:1659-1664.
19. Noedl H, Bironnet J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M: In vitro evaluation of the sensitivity of In vitro drug sensitivity assay for Plasmodium falciparum to antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum induced membrane damage by a catechol iron chelator in Plasmodium falciparum. Am J Trop Med Hyg 1999, 60:1658-1664.
20. Druilhe P, Moreno A, Bianco C, Brasseur PH, Jacquier P: Baso LK: In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1999, 41:120-125.
21. Schellert LW, Ashron SH, Trager W: Plasmodium falciparum: Microoxygen requirements in human red blood cells. Exp Parasitol 1979, 49.410-418.
22. Krungkrai J, Burat D, Kudan S, Krungkrai S, Prapunwattana P: Mitochondrial oxygen consumption in asexual and sexual blood stages of the human malarial parasite, Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1999, 30:636-642.
23. Jensen MD, Conley M, Helstowski LD: Culture of Plasmodium falciparum: the role of pH, glucose, and lactate. J Parasitol 1983, 69:1060-1067.
24. Krungkrai J, Yuwawong Y: The antimalarial action on Plasmodium falciparum of Qinghaosu and artesunate in combination with agents which modulates oxidant stress. Trans R Soc Trop Med Hyg 1987, 81:710-714.
25. Pradines B, Ramiaonisooa F, Fusai T, Hammedi A, Henry M, Briolan S, Orlandi-Pradines E, Bogreau H, Mosnier J, Baret E, Kunesch G, Le Bras J, Rogier C: Generation of free radicals and enhancement of hemin-induced membrane damage by a catechol iron chelator in Plasmodium falciparum. J Biol Chem 2005, 280:463-471.
26. Basco LK: Molecular epidemiology of malaria in cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am J Trop Med Hyg 2004, 70:474-480.
27. Pradines B, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, Trape JF, Parzy D: Antibiotics for prophylaxis of Plasmodium falciparum infections: in vitro activity of doxycycline against Senegalese isolates. Am J Trop Med Hyg 2000, 62:82-85.
28. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, Mosnier J, Callec A, Cren J, Malaviit R, Gardair JP, Rogier C: Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 2006, 44:2404-2408.
29. Dixian T, Bah IB, Ndiaye PM, Diallo I, Diop BM, Brasseur P, Mboob S, Wirth D, Ndir O: In vitro evaluation of the sensitivity of Plasmodium falciparum to chloroquine using the deli-microtest in region of Dakar, Senegal. Med Trop 2005, 65:580-583.
30. Briolan S, Parola P, Madamet-Torrentino M, Baret E, Mosnier J, Belmont J, Parzy D, Menard P, Rogier C, Pradines B: Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assay. Malar J 2007, 6:44.
31. Divo AA, Geary TG, Jensen JB: Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture. Antimicrob Agents Chemother 1985, 27:21-27.
32. Lin Q, Onda T, Kano S, Masuda G, Suzuki M: In vitro susceptibility test of Plasmodium falciparum using a portable thermostat and CO2 gas generator. Jpn Assoc Inf Dis 1999, 73:1099-1103.
33. He S, Saito-Ito A, Tanabe K, Matsumura T: Plasmodium falciparum: Effective use of the CO2-NaHCO3 buffer system for evaluating chloroquine resistance. Exp Parasitol 2000, 94:121-124.
34. Lombrac C, Vanderberg JP: Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 1979, 65:418-420.
35. Bogreau H, Renaud M, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wabe B, Adheshia E, Parola P, Kamil MA, Puajalon O, Rogier C: Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am J Trop Med Hyg 2006, 74:953-959.
36. Henry M, Diallo L, Bordes J, Ka S, Pradines B, Diatta B, Mbaye PS, Sane M, Thiam M, Gueye PM, Wade B, Touze JE, Debonheer JM, Roger C, Fusai T: Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg 2006, 75:146-151.
37. Le Bras J, Ringwald P: Plasmodium falciparum chemoresistance. The situation in Africa in 1989. Med Trop 1990, 50:161-162.
38. Basco LK, Le Bras J: In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artesinin derivatives. Am J Trop Med Hyg 1994, 58:137-144.
39. Hatin I, Trape JF, Legros F, Bauchet J, Le Bras J: Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area of Senegal, Bull WHO 1992, 70:363-367.
40. Basco LK, Bras Le: In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1993, 49:120-125.
41. Basco LK, Ramiaonisooa O, Le Bras J: In vitro activity of pyrimethamine, cycloguani and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1994, 50:193-199.
42. Schellert LW, Ashron SH, Trager W: Plasmodium falciparum: Microoxygen requirements in human red blood cells. Exp Parasitol 1979, 47:410-418.
43. Krungkrai J, Burat D, Kudan S, Krungkrai S, Prapunwattana P: Mitochondrial oxygen consumption in asexual and sexual blood stages of the human malarial parasite, Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1999, 30:636-642.
44. Jensen MD, Conley M, Helstowski LD: Culture of Plasmodium falciparum: the role of pH, glucose, and lactate. J Parasitol 1983, 69:1060-1067.
45. Krungkrai J, Yuwawong Y: The antimalarial action on Plasmodium falciparum of Qinghaosu and artesunate in combination with agents which modulates oxidant stress. Trans R Soc Trop Med Hyg 1987, 81:710-714.
46. Pradines B, Ramiaonisooa F, Fusai T, Hammedi A, Henry M, Briolan S, Orlandi-Pradines E, Bogreau H, Mosnier J, Baret E, Kunesch G, Le Bras J, Rogier C: Generation of free radicals and enhancement of hemin-induced membrane damage by a catechol iron chelator in Plasmodium falciparum. J Biol Chem 2005, 280:463-471.

doi:10.1186/1475-2875-10-8
Cite this article as: Pascual et al: Use of the atmospheric generators for canthophoric bacteria Genbag-CO2 for the evaluation of in vitro Plasmodium falciparum susceptibility to standard anti-malarial drugs. Malaria Journal 2011 10:8.